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 Vignette 
Daniel was diagnosed with diabetes at the age of 21. He was slim with a BMI of 20 kg/m2, presenting 
blood glucose was 15mmol/L, Hba1c 68mmol/mol (8.4%) and he reported symptoms of polyuria, 
polydipsia, nocturia and lethargy. He was given a diagnosis of Type 1 diabetes and was started 
immediately on basal bolus insulin. His mother was diagnosed with Type 1 diabetes at 26 years of 
age and she had always been insulin treated. His maternal grandfather, who was slim, was 
diagnosed with Type 2 diabetes in his 40s and was treated with Metformin. 
 
It was 7 years later when Daniel moved to another area that his local Genetic Diabetes Nurse 
questioned his diagnosis of Type 1 diabetes.  This was due to the autosomal dominant family history 
of diabetes and the fact that he remained on small doses of insulin (0.3u/kg/day) with good 
glycaemic control HbA1c 48mmol/mmol; 6.5%) despite admitting to omitting insulin on some 
occasions. His details were entered into the  MODY probability calculator 
(http://www.diabetesgenes.org/content/mody-probability-calculator) which indicated a 1 in 13 
chance of Daniel having Maturity Onset Diabetes of the young (MODY). This reflected an increased 
chance compared to the background prevalence of 1 in 143. As identifying a genetic diagnosis could 
potentially change Daniel’s treatment, further tests were undertaken.  
 
Islet autoantibodies to glutamate decarboxylase (GAD) and islet antigen-2 (IA-2) antibodies and Zinc 
transporter 8 (ZnT8) were tested and were all negative, increasing the suspicion that his diabetes 
may have a non-autoimmune cause. His Urinary C-Peptide Creatinine Ratio (UCPCR) seven years 
post diagnosis was 1.70nmol/mol, indicating that Daniel was continuing to make significant 
endogenous insulin which would not be expected in longstanding Type 1 diabetes. As a consequence 
of the UCPCR positivity, antibody negativity and dominant family history, genetic testing was 
undertaken.  A heterozygous mutation in HNF1A was identified and a diagnosis of HNF1A MODY was 
confirmed in Daniel.  
 
This correct molecular genetic diagnosis enabled Daniel to stop his insulin treatment and transfer to 
a low dose of sulphonylurea with improvements in quality of life. Family testing confirmed that both 
his mother and maternal grandfather were also heterozygous for the HNF1A mutation and therefore 
also had HNF1A MODY, and this diagnosis enabled them to change on to the most appropriate 
treatment with improvements in glycaemic control.  
 
Introduction 
Maturity onset diabetes of the young (MODY) is initially misdiagnosed as Type 1 or Type 2 diabetes 
in approximately 80% of cases resulting in inappropriate treatment and follow up (1-7). MODY is 
characterised by three key features: i) diabetes typically diagnosed less than 25 years in at least one 
family member, ii) autosomal dominant inheritance (with diabetes in a parent or child) and iii) non-
insulin dependent diabetes (or evidence of significant endogenous insulin production more than 
three years post diagnosis) (8). However the significance of these features may not be appreciated 
by healthcare professionals, leading to incorrect diagnosis and treatment. Poor recognition results in 
mean delays of >9 years from diabetes diagnosis to specific molecular genetic diagnosis, in many 
cases leading to years of unnecessary insulin treatment (9).  Early diagnosis of MODY is important as 
transfer from insulin to sulphonylurea is less likely to be successful with increasing duration of 
diabetes (10) 
Biomarker tests (islet autoantibodies and C-peptide) can help identify appropriate candidates for 
genetic testing for MODY, or other forms of monogenic diabetes, avoiding reliance on clinical 
recognition (11, 12). As these tests are not routinely used in clinical practice, identifying individuals 
diagnosed with diabetes below the age of 25 years with an affected parent or child may be a useful 
first step in detecting some of those in whom further testing may be warranted (Table 1). However 
islet autoantibody and C-peptide tests are cheap and easily available and can aid differential 
diagnosis (11-14). The free online MODY probability calculator or Diabetes Diagnostics App can also 
be used to identify those with a higher probability of having MODY 
http://www.diabetesgenes.org/content/mody-probability-calculator (15).   
 
This article provides some background on islet autoantibody, C-peptide and genetic tests for use in 
individuals with diabetes, including what samples are required, practical points to consider and 
where to find additional information. 
 
Islet autoantibodies  
Type 1 diabetes results from an autoimmune mediated destruction of the insulin producing 
pancreatic beta cells. Autoantibodies recognizing the islet cell antigens glutamic acid decarboxylase 
(GAD65), insulinoma antigen 2 (IA-2) and Zinc Transporter 8 (ZnT8) are present in up to 90% of newly 
diagnosed patients with Type 1 diabetes (16). Most individuals with Type 1 diabetes will have 
multiple islet autoantibodies detectable in their blood at diagnosis and less than 10% will have only 
one detectable antibody when assessed in combination (11).  
 
Testing islet autoantibodies could be considered the most helpful investigation to differentiate Type 
1 diabetes from MODY (11). The prevalence of GAD, IA-2 & ZnT8 autoantibodies is less than 1% in 
GCK, HNF1A and HNF4A MODY, and testing close to diagnosis gives very good discrimination of Type 
1 diabetes from MODY (11).  The difference in prevalence of autoantibodies between Type 1 
diabetes and MODY means these tests are useful in aiding differential diagnosis and identifying 
patients who may benefit from genetic testing. Although antibody testing close to diagnosis is 
recommended, GAD and IA2 remain detectable for many years and show high levels of diagnostic 
accuracy (17). Testing multiple antibodies is important as multiple antibody positivity increases the 
certainty of Type 1 diabetes and significantly increased the proportion of patients with a detectable 
antibody from approximately 60% with GAD only to over 80% with GAD and IA-2(11). Islet cell 
autoantibodies (ICA) was the first method for detecting islet autoantibodies.  ICA 
identifies the presence of human antibodies that bind to rodent or monkey pancreatic 
tissue, however the test is non standardised and the sensitivity can be as low as ~10% (i.e. 
9/10 with Type 1 diabetes have a negative result), ICA antibodies also disappear rapidly 
after diagnosis. ICA has now mostly been abandoned because of a poor diagnostic accuracy. 
Insulin autoantibodies (IAA) also have a lower sensitivity and as soon as exogenous insulin is 
given this is no longer a useful test. Therefore we recommend testing GAD, IA-2 and ZnT8 in 
combination.  
Local laboratories may test for autoantibodies but it is important to establish which tests they offer. 
ICA antibodies are not recommended as they are measured using a non standardised assay, have 
low reproducibility, low sensitivity and disappear rapidly after diagnosis (18) (See appendix 1 
available online at www. practicaldiabetes.com for further detail). 
 
Islet autoantibodies are most useful in enabling a firm diagnosis of Type 1 diabetes to be made in 
those who are antibody positive. This obviates the need for genetic testing as they are unlikely to 
have monogenic diabetes and if two antibodies are positive genetic testing is not indicated (11).  
Those previously considered to have Type 1 diabetes who are antibody negative should be 
considered for genetic testing, particularly if they have other features that would raise suspicion of 
MODY, for example a parent with diabetes or detectable levels of C-peptide. 
 
C-peptide  
C-peptide is made in equimolar amounts to insulin and is typically tested in patients on insulin 
treatment to assess endogenous insulin secretion.  Its role in individuals not on insulin treatment is 
limited. Those with long standing Type 1 diabetes typically have low or undetectable levels (<200 
pmol/L) indicating insulin deficiency (12). C-peptide may be present during the honeymoon period in 
Type 1 diabetes so when used to aid differential diagnosis is best measured at least 3 years  post 
diagnosis (19). 
 
Historically C-peptide was considered difficult to measure as it was previously recommended that 
the blood samples should be collected on ice, centrifuged immediately, and taken to the laboratory 
within 30 minutes (20), making the tests impractical within the general clinic setting. However 
urinary C-peptide creatinine ratio (UCPCR) is a simple, reliable, non-invasive measure which is stable 
for three days at room temperature (12,13). UCPCR can be measured on a post prandial sample 
taken approximately two hours after a meal stimuli, to identify the presence of endogenous insulin 
(21). This could either be taken two hours after the largest carbohydrate containing meal of the day 
and posted from home, or a random non fasting sample taken at a clinic visit (likely to be post 
breakfast or post lunch).  Samples should be taken in a boric acid tube and may be tested locally, or 
sent to the Exeter laboratory at the Royal Devon and Exeter NHS Foundation Trust. UCPCR costs 
<£12   http://www.exeterlaboratory.com/test/c-peptide-urine/ (Table 2). More recently it has been 
shown that plasma C-peptide is more stable than previously thought and there is no degradation 
within the first 24 hours on whole blood at room temperature when collected on EDTA (22). This 
presents another opportunity for easy and pragmatic assessment of endogenous insulin production 
on a blood sample collected in primary care or at a routine clinic visit.  
 
If the C-peptide result is ‘out of keeping’ with other clinical findings then the test should be 
repeated, especially if the result is unexpectedly low.  Patients ‘tipping out’ boric acid preservative 
from the urine collection tube, or a sample taking more than 3 days to reach the laboratory can 
result in artificially low results (13).  The interpretation of C-peptide levels depends on the specific 
clinical scenario i.e. type of diabetes and treatment. However UCPCR levels <0.2nmol/mmol, or 
stimulated blood C-peptide <200pmol/l, outside the honeymoon period indicate insulin deficiency 
which supports a diagnosis of Type 1 diabetes. UCPCR ≥0.2nmol/mol indicates endogenous insulin 
and has been used to differentiate patients with MODY from Type 1 diabetes >5 years post diagnosis 
(14).  In those with a diabetes duration >3 years with significant endogenous insulin an alternative 
diagnosis to Type 1 diabetes should be considered.  
 
Most of the studies of UCPCR have been performed in patients with normal renal function (eGFR >60 
mL/min/1.73 m2) but it has been validated in patients with Type 2 diabetes with moderate renal 
impairment (eGFR 30-60 mL/min/1.73 m2 (23).  However the test is not appropriate in patients with 
severe renal impairment. 
 
Online MODY probability calculator / Diabetes Diagnostic App 
Prior to genetic testing clinical details should be entered into the online MODY probability calculator 
(http://www.diabetesgenes.org/content/mody-probability-calculator) to establish the likelihood of 
MODY in each particular case. This takes into consideration other factors such as parental family 
history, initial and current treatment, gender, BMI, current age and age at diagnosis. These tools are 
for use in patients diagnosed with diabetes under the age of 35 and were developed on a European 
Caucasian cohort.  
 
There is no specific recommended probability ‘cut off’ for proceeding to genetic testing. The current 
pick-up rate for MODY testing in the UK is 25%, but where a diagnosis would make a difference to a 
patient's management, testing might still be considered appropriate at a lower probability.   
 
The Diabetes Diagnostics app is available for free download and combines the MODY clinical 
prediction calculator, information from national and international diabetes guidelines, and expert 
opinion from world leaders in monogenic diabetes to provide a resource to help guide diabetes 
classification. The app also includes data regarding other features that may be associated with 
different causes of monogenic diabetes (eg. Renal cysts) (see Table 3). 
 
Genetic testing for MODY 
In individuals, previously thought to have Type 1 diabetes, diagnosed <25 years of age who are islet 
autoantibody negative and C-peptide positive >3 years post diagnosis, an alternative diagnosis and 
genetic testing should be considered.  
 
The molecular genetic laboratory at the Royal Devon and Exeter NHS Foundation Trust carries out 
genetic testing for all known causes of MODY. EDTA whole blood (minimum 3ml)or genomic DNA 
samples (minimum 5ug) are required and should be sent at room temperature in the post 
(complying UN3373 postage requirements http://www.un3373.com/info/regulations/) along with a 
completed diagnostic request form (available to download at 
http://www.diabetesgenes.org/sites/default/files/mody_request_form.doc  (Table 2).  See appendix 
1 available online at www. practicaldiabetes.com for further detail. 
 
 
Conclusion 
Identifying individuals with monogenic diabetes is essential to ensure they receive optimal 
treatment. The correct molecular genetic diagnosis also enables follow up of family members and 
counselling regarding risk to their unaffected children. Non genetic tests (autoantibodies and C-
peptide) should be considered in individuals diagnosed below 25 years of age with an affected 
parent or child. These tests are cheap and easy to perform and, in combination with the online 
MODY probability calculator or Diabetes Diagnostics App, can help identify those in whom genetic 
testing may be appropriate. More information on diagnosing MODY, the tests available and the 
national network of Genetic Diabetes Nurses can be found on www.diabetesgenes.org .  
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1.  
Table 1. When to consider monogenic diabetes 
Consider monogenic diabetes in those with: Notes 
Diabetes diagnosed less than 6 months of age 
 
Free genetic testing for all patients diagnosed <6 months of age (whatever their age 
now) http://www.diabetesgenes.org/content/genetic-testing-neonatal-diabetes 
 
Diabetes diagnosed < 25 years with an affected parent or child  
 
Consider antibodies, c-peptide (in insulin treated patients) and enter details into 
MODY probability calculator / App prior to genetic testing 
http://www.diabetesgenes.org/content/mody 
 
Diabetes (young onset) plus other features associated with 
rare forms of monogenic diabetes  
Identify features associated with rare monogenic causes of diabetes and consider 
referral for genetic testing 
http://www.diabetesgenes.org/content/information-known-types-rare-diabetes 
 
 
  
Table 2. Tests aiding differential diagnosis of diabetes 
Test Analyte Sample collection Why test ? When to test  NHS cost Reporting 
time 
Result interpretation More information 
Islet 
autoantibodies 
GAD, IA2, 
ZnT8 
Clotted blood (1 x 7.5ml) 
for GAD, IA-2, ZnT8 only  
 
or EDTA whole blood 
(10ml adults; 5ml 
children; 1ml neonates) if 
DNA extraction for 
MODY testing is also 
required 
To 
differentiate 
between T1D  
and non T1D 
Ideally close to 
diagnosis but 
can still be 
positive many 
years post 
diagnosis 
£29.00 10 
working 
days 
Positive to 1 or more 
antibodies supports a 
diagnosis of Type 1 
diabetes.   
 
http://www.exeterlaboratory.c
om/test/gad-antibodies/ 
 
C-peptide 1. Blood C-
peptide  
 
 
2. Urinary C-
peptide 
creatinine 
ratio (UCPCR) 
Non fasting random 
sample in EDTA  
 
In Boric acid container, 
sample 2 hours after 
largest meal of the day, 
having emptied bladder 
before eating 
To 
differentiate 
between T1D 
and non T1D 
At least 3 or 
ideally more 
than 5 years 
post diabetes 
diagnosis 
£12.00 5 working 
days 
C-peptide > 
200pmol/L or UCPCR 
>0.2nmol/mol 
indicates endogenous 
insulin production 
 
http://www.exeterlaboratory.c
om/test/c-peptide-plasma/ 
 
 
 
http://www.exeterlaboratory.c
om/test/c-peptide-urine/ 
 
 
Genetic 
testing 
For individual 
MODY genes 
(e.g. GCK) or 
all known 
MODY genes 
in one test 
(tNGS) 
5-10ml venous blood in 
EDTA or >5µg DNA 
posted at room 
temperature. 
 
For mitochondrial 
diabetes testing only: 
Urine sample in a sterile 
white top universal 
container (from first pass 
urine of the day) 
To 
differentiate 
between T1D, 
T2D or 
monogenic 
diabetes 
At any time, 
although an 
earlier diagnosis 
will mean 
optimal 
treatment 
initiated earlier 
£75-£650 
depending 
on testing 
peformed. 
Individual 
genes - 3 
weeks  
 
tNGS - 6 
weeks 
Positive genetic test 
confirms specific 
MODY subtype which 
has implications for 
treatment and testing 
of family members.  
 
 
http://www.diabetesgenes.org
/content/diagnostic-tests-
available 
 
http://www.diabetesgenes.org
/content/new-test-all-mody-
genes 
 
 
tNGS = Targeted Next Generation Sequencing (of all known MODY genes) 
 Table 3. Additional features associated with the commonest causes of monogenic diabetes 
Gene Other features associated with the commonest causes of monogenic diabetes 
HNF1A MODY Low renal threshold for glucose 
Sensitive to low dose sulphonylureas 
Early myocardial infarction 
HNF4A MODY Sensitive to low dose sulphonylureas 
Macrosomia 
Neonatal hypoglycaemia 
Glucokinase MODY Mild stable hyperglycaemia: FBG 5.5-8mmol/L, HbA1c 40-60mmol/mol, small 
post-prandial increase in blood glucose (2 hour OGTT increment of <3mmol in 
70% of GCK MODY cases). 
HNF1B MODY Renal cysts or other renal developmental abnormality 
Low magnesium 
Low faecal elastase due to pancreatic hypoplasia 
Urogenital tract abnormality e.g. bicornuate uterus 
Early onset gout 
Autism (in those with whole gene deletions) 
Maternally inherited diabetes 
and deafness (MIDD) 
Maternally inherited diabetes 
Bilateral sensorineural deafness 
Short stature 
 Appendix 1 – Accessing tests aiding differential diagnosis:  Royal Devon and Exeter NHS Foundation Trust 
Islet autoantibodies  
 
The Blood Sciences department at the Royal Devon & Exeter NHS Foundation Trust offers a highly sensitive, automated ELISA method for the quantitative 
determination of GAD, IA-2 & ZnT8 autoantibodies in both serum and plasma samples for under £30  http://www.exeterlaboratory.com/test/islet-cell-
antibodies/ with results typically reported within ten working days (see Table 2 main article). Clotted samples should be sent if antibody testing only is 
required, but EDTA samples allow testing of antibodies and storage of DNA for subsequent MODY genetic testing if antibodies are negative, without the 
need for additional samples. Local laboratories may test for autoantibodies but it is important to establish which tests they offer. ICA antibodies are not 
recommended as they are measured using a non standardised assay, have low reproducibility, low sensitivity and disappear rapidly after diagnosis (18). 
 
C-Peptide  
The Blood Sciences department at the Royal Devon & Exeter NHS Foundation Trust accepts referrals for the analysis of urine c-peptide creatinine ratio (UCPCR). Urine should 
be collected in a boric acid container. The sample should be taken 2 hours after eating the largest meal of the day, having emptied the bladder before eating The samples are 
stable for 3 days at room temperature and cost of testing is around £12 http://www.exeterlaboratory.com/test/c-peptide-urine/ 
Alternatively plasma c-peptide can also be measured http://www.exeterlaboratory.com/test/c-peptide-plasma/ 
 
 
Genetic testing for MODY 
 
Individual genes can be tested if the clinical characteristics clearly suggest a particular type of MODY (for example if a patient has persistent fasting 
hyperglycaemia in the range of 5.5-8mmol/L, small post prandial increase in blood glucose and HbA1c always between 40-60mmol/mol then a diagnosis of 
GCK MODY is highly likely and testing for the GCK gene alone could be requested) (see Table 3 main article). The cost of testing individual genes varies from 
£75 for maternally inherited diabetes and deafness (MIDD) to £350 for GCK or HNF1B and £450 for combined HNF1A and HNF4A sequencing. However if 
the phenotype is not obvious it is preferable to request simultaneous analyses of all known MODY genes in a single test using targeted next generation 
sequencing (tNGS) at a cost of £650. The simultaneous testing of multiple genes by NGS increases the number of patients in whom a monogenic form of 
diabetes is identified (24). NGS testing also removes the need for detailed clinical phenotyping in order to determine which subtype of MODY the patient 
should be tested for. Results are usually available within 3 weeks for single gene tests or 6 weeks for tNGS, but samples can be prioritised for rapid result 
turnaround in specific circumstances (e.g.pregnancy).  A genetic diagnosis of MODY is made in approximately 20-25% of patients referred for MODY genetic 
testing in the UK.  Novel, previously unreported genetic variants are frequently identified in MODY genes (accounting for approximately 60% of all variants 
identified (25,26) and these require detailed investigation by clinical scientists to determine their clinical significance.  Referring clinicians have a key role to 
play in variant interpretation through gathering additional clinical information and recruiting family members for co-segregation studies. Support can be 
provided by the local Genetic Diabetes Nurse http://www.diabetesgenes.org/content/genetic-diabetes-nurses-locations-map . 
 
 
 
